Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
KOREA E & EX

Blood Test Measures Hodgkin’s Chemotherapy Success

By HospiMedica International staff writers
Posted on 06 Mar 2013
Print article
A cheap and easy to use diagnostic test helps determine the success of chemotherapy in patients enduring Hodgkin’s lymphoma (HL).

Researchers at the Queensland Institute of Medical Research (QIMR; Brisbane, Australia), the University of Melbourne (Australia), and other institutions prospectively measured serum CD163 (sCD163) and the Hodgkin-Reed-Sternberg (HRS)-specific serum protein sTARC in 221 samples taken from 47 patients with HL, and 21 healthy participants. Blood was drawn at five fixed time-points prior, during, and after first-line therapy. The results were compared with radiological assessment and plasma Epstein-Barr virus DNA (EBV-DNA). The researchers also examined potential sources of circulating CD163, as well as immunosuppressive properties of CD163.

The results showed that prior to therapy, both sCD163 and sTARC were markedly elevated compared with healthy and complete remission samples; sCD163 better reflected tumor burden during therapy, and sTARC presenting greater value upon completion of therapy. Additionally, sCD163 correlated with plasma EBV-DNA, and was associated with B symptoms, stage, and lymphopenia. The researchers found that the combination of both proteins was more informative as a disease response biomarker than either marker alone, in early and advanced disease during first-line therapy for classical HL. The study was published in the February 2013 issue of Clinical Cancer Research.

“This has the potential to be a huge aid for doctors in their decision making and a faster and less invasive process for the patients. Up until now, clinicians have relied on scans to help them judge how well people are responding to chemotherapy,” said lead author Professor Maher Gandhi, PhD, of the QIMR Clinical Immunohaematology Laboratory. “This discovery means we can work towards using simple blood tests to provide quicker, cheaper, and more regular monitoring of how a person is responding to treatment.”

Response biomarkers for classical HL might arise from Hodgkin-Reed-Sternberg (HRS) cells or nonmalignant tumor-infiltrating cells. While HRS cells are sparse within the diseased node, benign CD163(+) M2 tissue-associated macrophages (TAM) are prominent. It is known that CD163(+) cells within the malignant node may be prognostic, but until now there has been no data on serum CD163.

Related Links:

Queensland Institute of Medical Research
University of Melbourne



Print article
LevMed LTD.

Channels

Surgical Techniques

view channel

Coronary Clot Aspiration Provides No MI Survival Benefit

Thrombectomy did not improve outcomes for myocardial infarct (MI) patients presenting after symptom onset, according to a new study. Researchers at University College London (UCL; United Kingdom), the University of Manchester (United Kingdom), and other institutions conducted a retrospective study based on a UK national... Read more

Women's Health

view channel
Image: The Eclipse vaginal insert in deflated (L) and Inflated (R) states (Phoyo courtesy of Pelvalon).

Vaginal Insert Offers Alternative Treatment for Fecal Incontinence

A novel vaginal insert for bowel control eliminates the need for surgery or an in-office procedure for the treatment of female fecal incontinence (FI). The second-generation Eclipse System is comprised... Read more

Health IT

view channel
Image: The Rigel 62353 Plus tester (Photo courtesy of Rigel Medical).

Advanced Safety Tester Analyzes Diverse Medical Devices

An upgraded dedicated tester meets international standards for in-service and post-repair safety testing of 24 V and 48 V DC medical electronic devices. The Rigel 62353 Plus tester offers a range of... Read more

Hospital News

view channel
Image: Site of the new HSS outpatient center in Westchester County (Photo courtesy of the RPW Group).

Hospital for Special Surgery Opens New Outpatient Center

The Hospital for Special Surgery (HSS; New York, NY, USA) has leased a 4,645 m² space in White Plains (NY, USA) from RPW Group (Rye Brook, NY, USA), which will serve as the new HSS outpatient center in... Read more

Business

view channel

Global Call for Action Against Drug-Resistant Infections

More than 80 leading international bodies came together to call on governments and industry to work in parallel and take comprehensive action against drug-resistant infections, as proclaimed in a joint declaration released at the World Economic Forum (Cologny, Switzerland), held during January 2016 in Davos (Switzerland).... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.